Phaseline

Companies › March Biosciences

March Biosciences: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Feb 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
MB-105
CD5-targeted CAR T-cell therapy
CD5Phase 2Lymphoma, T-CellFeb 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06534060MB-105Phase 2Lymphoma, T-CellOncologyFeb 2028

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

CD5 (1)

Companies with the same targets

Vittoria Biotherapeutics Chongqing Precision Biotech Beijing Biotech

Companies built like this

Newish Technology (Beijing) BrainChild Bio TVAX Biomedical Lukas Biomedical RhoVac APS

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.